首页> 美国卫生研究院文献>Journal for Immunotherapy of Cancer >Phase I study of safety and immunogenicity of ADU-623 a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1 in patients with who grade III/IV astrocytomas

【2h】

Phase I study of safety and immunogenicity of ADU-623 a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1 in patients with who grade III/IV astrocytomas

机译：III期或IV级星形细胞瘤患者中表达EGFRVIII和NY-ESO-1的减毒活单核细胞增生李斯特菌疫苗（ΔactA/ΔinlB）ADU-623的安全性和免疫原性的I期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Journal for Immunotherapy of Cancer
作者
Marka Crittenden; Keith S Bahjat; Rui Li; Pankaj Gore; Chris Fountain; Bill Hanson; Justin Skoble; Peter Lauer; Aimee L Murphy; Thomas Dubensky; Dirk G Brockstedt; Walter Urba;
展开▼
作者单位

展开▼
年(卷),期 2015(3),Suppl 2
年度 2015
页码 P162
总页数 2
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献

1. Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas [J] . Marka Crittenden, Keith S Bahjat, Rui Li, Journal for ImmunoTherapy of Cancer . 2015 ,第S2期

机译：III期或IV级星形细胞瘤患者中表达EGFRVIII和NY-ESO-1的减毒单核细胞增生李斯特菌活疫苗（ΔactA/ΔinlB）ADU-623的安全性和免疫原性的I期研究
2. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase i studies of safety and immune induction. [J] . Dung T Le, Dirk G Brockstedt, Ran Nir-Paz, Clinical cancer research: an official journal of the American Association for Cancer Research . 2012 ,第3期

机译：表达减毒活的李斯特菌减毒活疫苗（ANZ-100）和表达间皮素的减毒李斯特菌活疫苗（CRS-207）：安全性和免疫诱导的第一阶段研究。
3. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix [J] . Maciag Paulo Cesar, Radulovic Sinisa, Rothman John Vaccine . 2009 ,第30期

机译：减毒李斯特菌减毒活疫苗的首次临床应用：Lm-LLO-E7在子宫颈晚期癌患者中的I期安全性研究
4. A Live-attenuated Listeria Vaccine (ANZ-100) and a Live-attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase 1 Studies of Safety and Immune Induction [O] . Dung T. Le, Dirk G. Brockstedt, Ran Nir-Paz, -1

机译：活衰减的李斯特菌疫苗（ANZ-100）和表达中学疫苗的活病毒疫苗（CRS-207）用于晚期癌症：第1期安全性和免疫诱导研究
5. Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas [O] . 2015

机译：III期或IV级星形细胞瘤患者中表达EGFRVIII和NY-ESO-1的减毒活单核细胞增生李斯特菌疫苗（ΔactA/ΔinlB）ADU-623的安全性和免疫原性的I期研究
6. Randomized Double-Blind Phase III Pivotal Field Trial of the Comparative Immunogenicity Safety and Tolerability of Two Yellow Fever 17D Vaccines (ARILVAX(Trademark) and YF-VAX(Trademark)) in Healthy Infants and Children in Peru [R] . Belmusto-Worn, V. E. , Sanchez, J. L. , McCarthy, K. , 2004

机译：秘鲁健康婴儿和儿童两种黄热病17D疫苗（aRILVaX（商标）和YF-VaX（商标））的比较免疫原性安全性和耐受性的随机双盲III期关键现场试验

Phase I study of safety and immunogenicity of ADU-623 a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1 in patients with who grade III/IV astrocytomas

著录项

相似文献

相关主题

期刊订阅